Tobin Schilke insider trades: Crinetics Pharmaceuticals (CRNX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Tobin reports to the SEC
Open-market buys and sales
17 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | CRNX | ↓ Sell | 6,713 | $39.67 | $266K | Direct | Mar 4, 2026 (1d) |
| Mar 18, 2024 | RVNC | ↓ Sell | 9,361 | $5.04 | $47K | Direct | Mar 19, 2024 (1d) |
| Jul 3, 2023 | RVNC | ↓ Sell | 1,701 | $25.04 | $43K | Direct | Jul 5, 2023 (2d) |
| Jun 2, 2023 | RVNC | ↓ Sell | 3,201 | $30.64 | $98K | Direct | Jun 5, 2023 (3d) |
| May 15, 2023 | RVNC | ↓ Sell | 21,401 | $34.55 | $739K | Direct | May 16, 2023 (1d) |
| May 1, 2023 | RVNC | ↓ Sell | 3,201 | $31.70 | $101K | Direct | May 2, 2023 (1d) |
| Apr 3, 2023 | RVNC | ↓ Sell | 3,201 | $32.15 | $103K | Direct | Apr 4, 2023 (1d) |
| Mar 9, 2023 | RVNC | ↓ Sell | 18,517 | $31.59 | $585K | Direct | Mar 9, 2023 (0d) |
| Mar 1, 2023 | RVNC | ↓ Sell | 3,201 | $33.50 | $107K | Direct | Mar 2, 2023 (1d) |
| Feb 1, 2023 | RVNC | ↓ Sell | 3,201 | $34.60 | $111K | Direct | Feb 2, 2023 (1d) |
| Jan 20, 2023 | RVNC | ↓ Sell | 1,000 | $31.00 | $31K | Direct | Jan 23, 2023 (3d) |
| Jan 9, 2023 | RVNC | ↓ Sell | 3,701 | $27.16 | $101K | Direct | Jan 10, 2023 (1d) |
| Jun 26, 2018 | AKAO | ↓ Sell | 298 | $9.59 | $3K | Direct | Jun 28, 2018 (2d) |
| Jun 11, 2018 | AKAO | ↓ Sell | 2,087 | $11.95 | $25K | Direct | Jun 13, 2018 (2d) |
| Feb 21, 2018 | AKAO | ↓ Sell | 1,108 | $10.67 | $12K | Direct | Feb 23, 2018 (2d) |
| Jun 12, 2017 | AKAO | ↓ Sell | 2,066 | $21.53 | $44K | Direct | Jun 14, 2017 (2d) |
| Jan 26, 2017 | AKAO | ↓ Sell | 955 | $16.78 | $16K | Direct | Jan 30, 2017 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other CRNX insiders
Open-market trades in the last 12 months
About Tobin Schilke's insider trades
Tobin Schilke is Chief Financial & Infra. Ofcr. at Crinetics Pharmaceuticals (CRNX). Since Jan 26, 2017, Tobin has reported no open-market purchases and 17 sales worth $2.4M on SEC Form 4. In the last 12 months: 1 sale ($266K).
Their filings also include grants and awards (27 filings), shares withheld for taxes (13 filings), other transactions (7 filings), shares returned to the company (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CRNX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.